Impact of musculoskeletal disease on quality of life in long-standing acromegaly

Miller, Anne; Doll, Helen; David, Joel; Wass, John

doi:10.1530/eje-07-0838

Cited by 81 publications

(60 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although most reports on QoL using generic questionnaires in NFPA describe a low QoL after treatment (7,11,41,75,76), there are also descriptions of normalization of QoL, after successful treatment, attaining scores comparable to those seen in a healthy population (77,78). As already mentioned, compared to that of other pituitary adenoma patients, QoL of NFPA patients was similar to that of patients treated for prolactinoma, and better than that of patients diagnosed with CD and acromegaly (11,39,79,80).…”

Section: Non-functioning Pituitary Adenomasmentioning

confidence: 83%

See 1 more Smart Citation

MANAGEMENT OF ENDOCRINE DISEASE: Quality of life tools for the management of pituitary disease

Webb

Crespo

Santos

et al. 2017

European Journal of Endocrinology

View full text Add to dashboard Cite

Background: In the last few years, quality of life (QoL) has become an outcome measure in patients with pituitary diseases. Objective: To describe the available data on QoL impairment evaluated with questionnaires in patients with pituitary diseases. Design: Critical review of the pertinent literature and pragmatic discussion of available information. Methods: Selection of relevant literature from PubMed and WOK, especially from the last 5 years and comprehensive analysis. Results: QoL is impaired in all pituitary diseases, mostly in acromegaly and Cushing's disease (similar to other causes of Cushing's syndrome), but also in non-functioning pituitary adenomas and prolactinomas, especially in the active phase of the disease. Nevertheless, even after endocrine 'cure', scores tend to be below normative values, indicative of residual morbidity after hormonal control. The presence of hypopituitarism worsens subjective QoL perception, which can improve after optimal substitution therapy, including recombinant human growth hormone, when indicated. Conclusions: To improve the long-term outcome of pituitary patients, helping them to attain the best possible health, it appears desirable to include subjective aspects captured when evaluating QoL, so that the affected dimensions are identified and if relevant treated. Additionally, being aware that treatment outcome may not always mean complete normalisation of physical and mental issues related to QoL can be a first step to adaptation and conforming to this new status.

show abstract

Section: Non-functioning Pituitary Adenomasmentioning

confidence: 83%

“…Apart from the disease activity, worse QoL has been observed if patients complain of persistent headache or musculoskeletal pain (38,39). When comparing disease control after surgery or due to on-going medical therapy, QoL scores are usually better when no chronic treatment is required (40).…”

Section: Acromegalymentioning

confidence: 99%

MANAGEMENT OF ENDOCRINE DISEASE: Quality of life tools for the management of pituitary disease

Webb

Crespo

Santos

et al. 2017

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Skeletal Acromegalic arthropathy can affect up to 84% of the cases (depending on the affected joint ;Miller et al 2008), especially older patients or females (Kropf et al 2013). Carpal tunnel syndrome occurs in 20-40% of cases.…”

Section: Complicationsmentioning

confidence: 99%

“…Carpal tunnel syndrome occurs in 20-40% of cases. Musculoskeletal pain is extremely prevalent and adversely impacts the quality of life (QoL; Miller et al 2008).…”

Section: Complicationsmentioning

confidence: 99%

60 YEARS OF NEUROENDOCRINOLOGY: Acromegaly

Căpățînă¹,

Wass²

2015

Journal of Endocrinology

View full text Add to dashboard Cite

Acromegaly (ACM) is a chronic, progressive disorder caused by the persistent hypersecretion of GH, in the vast majority of cases secreted by a pituitary adenoma. The consequent increase in IGF1 (a GH-induced liver protein) is responsible for most clinical features and for the systemic complications associated with increased mortality. The clinical diagnosis, based on symptoms related to GH excess or the presence of a pituitary mass, is often delayed many years because of the slow progression of the disease. Initial testing relies on measuring the serum IGF1 concentration. The oral glucose tolerance test with concomitant GH measurement is the gold-standard diagnostic test. The therapeutic options for ACM are surgery, medical treatment, and radiotherapy (RT). The outcome of surgery is very good for microadenomas (80-90% cure rate), but at least half of the macroadenomas (most frequently encountered in ACM patients) are not cured surgically. Somatostatin analogs are mainly indicated after surgical failure. Currently their routine use as primary therapy is not recommended. Dopamine agonists are useful in a minority of cases. Pegvisomant is indicated for patients refractory to surgery and other medical treatments. RT is employed sparingly, in cases of persistent disease activity despite other treatments, due to its long-term side effects. With complex, combined treatment, at least three-quarters of the cases are controlled according to current criteria. With proper control of the disease, the specific complications are partially improved and the mortality rate is close to that of the background population.

show abstract

“…Biermesz et al showed that the presence of joint problems is associated with reduced scores on several different QoL questionnaires. Acromegalic patients have a high prevalence of joint-related comorbidity and -very importantly -joint complaints contributed to a reduction in these patients' perceived quality of life [37].…”

Section: Acromegaly and The Quality Of Lifementioning

confidence: 99%

The Quality of Life and Psychological, Social and Cognitive Functioning of Patients with Acromegaly

Szczęśniak¹,

Jawiarczyk-Przybyłowska²,

Rymaszewska³

2015

Adv Clin Exp Med

View full text Add to dashboard Cite

Acromegaly is a rare and chronic disease, most often caused by a pituitary adenoma. Excessive secretion of the growth hormone (GH) leads to hepatic secretion of insulin-like growth factor-1 (IGF-1), which in turn causes characteristic changes in the patient's appearance, many skeletal deformities and metabolic disorders. In addition to somatic symptoms, acromegalic patients demonstrate psychosocial and personality deficits, as well as common co-occurrence of mental disorders. There are few studies investigating acromegaly in Poland. In recent years, the concept of quality of life has become fundamental to understanding health problems. Studies dealing with acromegaly likewise tend to include assessments of quality of life of patients suffering from this endocrinopathy (Adv Clin Exp Med 2015, 24, 1, 167-172).

show abstract

Impact of musculoskeletal disease on quality of life in long-standing acromegaly

Cited by 81 publications

References 22 publications

MANAGEMENT OF ENDOCRINE DISEASE: Quality of life tools for the management of pituitary disease

MANAGEMENT OF ENDOCRINE DISEASE: Quality of life tools for the management of pituitary disease

60 YEARS OF NEUROENDOCRINOLOGY: Acromegaly

The Quality of Life and Psychological, Social and Cognitive Functioning of Patients with Acromegaly

Contact Info

Product

Resources

About